Cargando…
Vaccine allergy: evidence to consider for COVID-19 vaccines
Whereas the COVID-19 pandemic has changed our lives worldwide, we hope that vaccination can combat the disease. We propose how to evaluate suspected severe allergic reactions to the vaccines so that as many as possible may be safely vaccinated. RECENT FINDINGS: Rare cases of severe allergic reaction...
Autores principales: | , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Lippincott Williams & Wilkins
2021
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8270228/ https://www.ncbi.nlm.nih.gov/pubmed/34091550 http://dx.doi.org/10.1097/ACI.0000000000000762 |
_version_ | 1783720758194733056 |
---|---|
author | Nilsson, Lennart Csuth, Ágnes Storsaeter, Jann Garvey, Lene H. Jenmalm, Maria C. |
author_facet | Nilsson, Lennart Csuth, Ágnes Storsaeter, Jann Garvey, Lene H. Jenmalm, Maria C. |
author_sort | Nilsson, Lennart |
collection | PubMed |
description | Whereas the COVID-19 pandemic has changed our lives worldwide, we hope that vaccination can combat the disease. We propose how to evaluate suspected severe allergic reactions to the vaccines so that as many as possible may be safely vaccinated. RECENT FINDINGS: Rare cases of severe allergic reactions after COVID-19 vaccination have been observed, seemingly at a higher frequency than for other vaccines. Few excipients are likely to have caused these reactions. IgE-mediated reactions to polyethylene glycol (PEG) and its derivatives are the most suspected, albeit hitherto unproven, causes. We suggest to make a diagnosis based on skin tests with PEG and PEG derivatives and that these be considered in relation to the decisions required before the first and the second vaccine dose. A vaccine without these excipients is available, but published data about its side effects are limited. SUMMARY: The underlying immunological mechanisms of the rare severe allergic reactions to the COVID-19 vaccines are poorly understood and need to be clarified. Identifying those who have an undiagnosed allergy to PEG and PEG derivatives is crucial before vaccination, and these substances are found in laxatives, cosmetics and in 30% of all our medications today. |
format | Online Article Text |
id | pubmed-8270228 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2021 |
publisher | Lippincott Williams & Wilkins |
record_format | MEDLINE/PubMed |
spelling | pubmed-82702282021-07-12 Vaccine allergy: evidence to consider for COVID-19 vaccines Nilsson, Lennart Csuth, Ágnes Storsaeter, Jann Garvey, Lene H. Jenmalm, Maria C. Curr Opin Allergy Clin Immunol PHARMACOTHERAPY AND EVIDENCE BASED MEDICINE: Edited by Enrico Compalati and Derek Chu Whereas the COVID-19 pandemic has changed our lives worldwide, we hope that vaccination can combat the disease. We propose how to evaluate suspected severe allergic reactions to the vaccines so that as many as possible may be safely vaccinated. RECENT FINDINGS: Rare cases of severe allergic reactions after COVID-19 vaccination have been observed, seemingly at a higher frequency than for other vaccines. Few excipients are likely to have caused these reactions. IgE-mediated reactions to polyethylene glycol (PEG) and its derivatives are the most suspected, albeit hitherto unproven, causes. We suggest to make a diagnosis based on skin tests with PEG and PEG derivatives and that these be considered in relation to the decisions required before the first and the second vaccine dose. A vaccine without these excipients is available, but published data about its side effects are limited. SUMMARY: The underlying immunological mechanisms of the rare severe allergic reactions to the COVID-19 vaccines are poorly understood and need to be clarified. Identifying those who have an undiagnosed allergy to PEG and PEG derivatives is crucial before vaccination, and these substances are found in laxatives, cosmetics and in 30% of all our medications today. Lippincott Williams & Wilkins 2021-08 2021-06-17 /pmc/articles/PMC8270228/ /pubmed/34091550 http://dx.doi.org/10.1097/ACI.0000000000000762 Text en Copyright © 2021 The Author(s). Published by Wolters Kluwer Health, Inc. https://creativecommons.org/licenses/by-nc-nd/4.0/This is an open access article distributed under the terms of the Creative Commons Attribution-Non Commercial-No Derivatives License 4.0 (CCBY-NC-ND), where it is permissible to download and share the work provided it is properly cited. The work cannot be changed in any way or used commercially without permission from the journal. http://creativecommons.org/licenses/by-nc-nd/4.0 (https://creativecommons.org/licenses/by-nc-nd/4.0/) This article is made available via the PMC Open Access Subset for unrestricted re-use and analyses in any form or by any means with acknowledgement of the original source. These permissions are granted for the duration of the COVID-19 pandemic or until permissions are revoked in writing. Upon expiration of these permissions, PMC is granted a perpetual license to make this article available via PMC and Europe PMC, consistent with existing copyright protections. |
spellingShingle | PHARMACOTHERAPY AND EVIDENCE BASED MEDICINE: Edited by Enrico Compalati and Derek Chu Nilsson, Lennart Csuth, Ágnes Storsaeter, Jann Garvey, Lene H. Jenmalm, Maria C. Vaccine allergy: evidence to consider for COVID-19 vaccines |
title | Vaccine allergy: evidence to consider for COVID-19 vaccines |
title_full | Vaccine allergy: evidence to consider for COVID-19 vaccines |
title_fullStr | Vaccine allergy: evidence to consider for COVID-19 vaccines |
title_full_unstemmed | Vaccine allergy: evidence to consider for COVID-19 vaccines |
title_short | Vaccine allergy: evidence to consider for COVID-19 vaccines |
title_sort | vaccine allergy: evidence to consider for covid-19 vaccines |
topic | PHARMACOTHERAPY AND EVIDENCE BASED MEDICINE: Edited by Enrico Compalati and Derek Chu |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8270228/ https://www.ncbi.nlm.nih.gov/pubmed/34091550 http://dx.doi.org/10.1097/ACI.0000000000000762 |
work_keys_str_mv | AT nilssonlennart vaccineallergyevidencetoconsiderforcovid19vaccines AT csuthagnes vaccineallergyevidencetoconsiderforcovid19vaccines AT storsaeterjann vaccineallergyevidencetoconsiderforcovid19vaccines AT garveyleneh vaccineallergyevidencetoconsiderforcovid19vaccines AT jenmalmmariac vaccineallergyevidencetoconsiderforcovid19vaccines |